Ferring Strengthens Growth Hormone Franchise Zomacton® Through Acquisition of ZomaJet™ Needle-Free Injector Device
Ferring Pharmaceuticals announced today that it has entered into a definitive agreement with Antares Pharma, Inc. to acquire the worldwide rights for the ZomaJet™ needle-free auto injector device.
This transaction is subject to customary closing conditions. Antares will continue to manufacture and supply the ZomaJet device until completion of existing supply arrangements, expected by the end of 2018.
ZomaJet is used to deliver Ferring’s Zomacton® (somatropin), a treatment indicated for the treatment of Growth Hormone Deficiency (GHD) in children and Turner Syndrome in girls.
“Through the acquisition of ZomaJet, we are consolidating our Zomacton franchise and commitment to improving quality of life and care for children with growth disorders,” said Michel Pettigrew, President of the Executive Board and Chief Operating Officer, Ferring Pharmaceuticals. “ZomaJet addresses the common problem of needle fear in children, lowering the burden for patients and care givers and leading to better adherence to treatment.”
Ferring is a recognised speciality player in endocrinology, with a commitment to addressing the unmet medical needs of patients with childhood growth disorders including GHD and Turner Syndrome.
ZomaJet devices are needle-free delivery systems for the administration of Zomacton® (somatropin) human growth hormone (hGH).
About Zomacton ®
Zomacton® (somatropin) is a synthetic human growth hormone (hGH) produced by recombinant DNA technology. The main use for the product is to treat Growth Hormone Deficiency (GHD) in children and Turner Syndrome in girls.
About Ferring Pharmaceuticals:
Headquartered in Saint-Prex, Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. A leader in reproductive and maternal health, Ferring has been developing treatments for mothers and babies for over 50 years. Today, over one third of the company’s research and development investment goes towards finding innovative treatments to help mothers and babies, from conception to birth. The company also identifies, develops and markets innovative products in the areas of urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries. For further information on Ferring or its products, visit www.ferring.com .
Ferring is on Twitter. Follow us @FerringNews at http://twitter.com/FerringNews
1 Haverkamp F. & Gasteyger G. Journal of Medical Economics 2011; 14(4): 448-457
2 Wickramasuriya B.P. et al , Horm Res 2006; 65(1): 18-22
3 Main K.M. et al , Acta Paediatr 1995; 84(3): 331-334
Ferring Corporate Communications Team:
Senior Manager, Corporate Communications
+41 58 451 4023 (direct)
+41 79 191 0486 (mobile)
Head of Corporate Communications
+41 58 301 0952 (direct)
+41 79 191 0632 (mobile)
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
GA-CELLTRION-HEALTHCARE11.12.2017 09:02 | pressemeddelelse
Top UK university hospital unveils data that support the use of rapid infusion for Truxima® (CT-P10, biosimilar rituximab) in patients with advanced-stage follicular lymphoma
DIMOCO-EUROPE11.12.2017 09:02 | pressemeddelelse
Financial Market Regulator Grants EU Payment License to DIMOCO Payment Services
SES11.12.2017 08:57 | pressemeddelelse
4KUNIVERSE to Launch in Swiss TV Households via SES
ADC-THERAPEUTICS11.12.2017 07:32 | pressemeddelelse
ADC Therapeutics Announces Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-301
ADC-THERAPEUTICS11.12.2017 07:02 | pressemeddelelse
ADC Therapeutics Presents Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-402
FL-GA-TELESIS11.12.2017 06:03 | pressemeddelelse
GA Telesis Launches Leveraged Finance Group with the Appointments of David Lloyd and Nolan Heske
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum